Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respirato...
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
About this item
Full title
Author / Creator
Publisher
Heidelberg: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Heidelberg: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
Lower respiratory tract infection (LRTI) is the leading cause of infant mortality globally in post-neonatal infants (i.e., 28–364 days of age). Respiratory syncytial virus (RSV) is the most commonly identified pathogen for infant LRTI and is the second most important cause of death in post-neonatal infants. Despite 50 years of RSV v...
Alternative Titles
Full title
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4269625
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4269625
Other Identifiers
ISSN
2193-8229
E-ISSN
2193-6382
DOI
10.1007/s40121-014-0046-6
